期刊文献+

人脑胶质瘤多药耐药细胞株的构建及生物学特性鉴定 被引量:1

Establishment of human glioblastoma multiform multidrug resistant cell line in vitro and identification of its biological characteristics
原文传递
导出
摘要 目的体外构建胶质瘤耐甲磺酸伊玛替尼多药耐药细胞株,并研究其生物学特性。方法采用逐渐增加培养基中伊玛替尼药物浓度的方法诱导构建耐甲磺酸伊玛替尼的人脑胶质瘤U251细胞株(命名为U251AR);CCK8法检测U25IAR、U251对多种化疗药物的IC50和耐药指数;QRT-PCR法检测耐药相关基因ABCC1、ABCB1、ABCB4、ABCG2mRNA的表达,流式细胞术检测ABCG2蛋白的表达。结果体外培养12个月后建立了稳定耐药的细胞株U251AR,与亲代细胞相比异形性不显著。U251和U251AR对化疗药物的IC50相比较差异均有统计学意义(P〈0.05),U251AR对甲磺酸伊玛替尼、阿霉素、顺铂的耐药指数分别为20.41、5.06、10.28,表现出多药耐药特征。QRT-PCR检测结果显示耐药细胞株U251AR中ABCC1、ABCB1、ABCB4、ABCG2mRNA的表达明显高于亲代U251细胞,流式细胞术检测结果显示U251AR中ABCG2蛋白的表达强于亲代U251细胞,差异均有统计学意义(P〈0.05)。结论成功建立多药耐药的胶质瘤细胞株U251AR,其多药耐药与ABCCl、ABCB1、ABCB4、ABCG2mRNA及ABCG2蛋白的表达上调相关。 Objective To establish the imatinib (STI-571)-resistant subline in vitro and investigate its biological characteristics. Methods Human gliobLastoma multiform drug-resistant cell line (named U251AR) was established in vitro by successively increasing the concentration of imatinib in a cell culture medium. The 50% inhibitory dose (IC50) values and the resistance indexes ([IC50 U251/STI-571 ]/[IC50 U251 ]) for other chemotherapeutic agents were evaluated using cell counting kit-8 assays. Expressions of acquired multidrug resistance P-glycoprotein (MDR1, ABCB 1; MDR3, ABCB4), breast cancer resistance protein (BCRP, ABCG2) and multidrug resistance-associated protein 1 (MRP1, ABCC1) were detected by QRT-PCR. Flow cytometry was employed to detect the protein expression of ABCG2. Results The U251AR was developed after culture for 12 months and similar morphologies of U251 and U251/STI-571 cells were determined. The resistance coefficient of U251AR cells to imatinib was 20.41 times more than that of the parent cells, and U251AR cells showed cross-resistance to many anti-tumor agents (P〈0.05). The resistance coefficients of U251AR cell line to doxorubicin and cisplatin were 5.06 and 10.28 times, respectively, more than those of U251 cells (P〈0.05). QRT-PCR indicated that the mRNA levels ofMDR1, MRP1, BCRPandABCB4 (P-g4) in the U251/STI571 resistant cells were significantly higher than those in the U251 cells (P〈0.05). The protein expression of ABCG2 in U251AR cell line was significantly increased as compared with that in the parent cells (P〈0.05).Conclusion We have successfully established multidrug resistant cell line U251AR, and the drug resistance of U251/STI571 is associated with over-expressions of A BCC1, A BCB1, A BCB4, and A BCG2 mRNA, and ABCG2 protein.
出处 《中华神经医学杂志》 CAS CSCD 北大核心 2011年第8期764-767,共4页 Chinese Journal of Neuromedicine
基金 基金项目:国家自然科学基金(81041068,30971183) 广东省科技计划(20098030801230) 广东省自然科学基金(7005213)
关键词 神经胶质瘤 甲磺酸伊玛替尼 多药耐药性 细胞株 Glioblastoma Imatinib Mesylate Multidrug resistance Cell line
  • 相关文献

参考文献8

  • 1Kang HC, Kin IJ, Park JH, et al. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using highdensity oligonucleotide mieroarrays [J]. Clinical Cancer Res, 2004, 10(pt 1): 272-284.
  • 2Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment [J]. Curr Med Chem, 2006, 13 (16): 1859-1876.
  • 3Stupp R, Mason WP, van den Bent MJ. et al. Radiotherapy plus concomitant and adjuvanttemozolomide for glioblastoma [J]. N Engl J Med, 2005, 352(10): 987-896.
  • 4Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study[J]. Cancer Res, 2004, 64 (19): 6892-6899.
  • 5Bai RY, Staedtke V, Riggins GJ. Molecular targeting of glioblastoma: drug discovery and therapies [J]. Trends Mol Med, 2011, 17(6): 301-312.
  • 6Druker B J, Talpaz M, Resta D J, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia[J]. N Engl J Med, 2001, 344(14): 1031-1037.
  • 7钟萍,李云峰.腹膜恶性间皮瘤6例临床分析[J].实用医学杂志,2007,23(17):2724-2725. 被引量:5
  • 8Hegedus T, Orfi L, Seprodi A, et al. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins,MDR1 and MRP1 [J]. Biochim Biophys Acta, 2002, 1587(2-3): 318-325.

二级参考文献7

共引文献4

同被引文献19

  • 1Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit f:om temozolomide in glioblastoma [J]. N Engl J Med, 2005, 352(10): 997-1003.
  • 2Yue Z, Jin S, Yang C, et al. Beelin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor [J]. Proc Natl Acad Sci U S A, 2003, 100 (25): 15077-15082.
  • 3Bai Y, Liao H, Liu T, et al. MiR-296-3p regulates eel1 growth and multi-drug resistanee of human glioblastoma by targeting ether-a-go-go (EAG1)[J]. Eur J Cancer, 2013, 49(3): 710-724.
  • 4Pirtoli L, Cevenini G, Tini P, et al. The prognostic role of Beelin 1 protein expression in high-grade gliomas [J]. Autophagy, 2009, 5 (7): 930-936.
  • 5Geng QR, Xu DZ, He LJ, et al. Beclin-1 expression is a significant predictor of survival in patients with lymph node-positive gastriccancer[J]. PLoS One, 2012, 7(9): e45968.
  • 6Wan XB, Fan XJ, Chen MY, et al. Elevated Beclin 1 expression is correlated with HIF-lalpha in predicting poor prognosis of nasopharyngeal carcinoma[J]. Autophagy, 2010, 6(3): 395-404.
  • 7Giatromanolaki A, Koukourakis MI, Koutsopoulos A, et al. High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas[J]. Gynecol Oncol, 2011,123(1): 147-151.
  • 8Chen Y, Lu Y, Lu C, et al. Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxia-inducible factor (HIF)-lalpha expression[J]. Pathol Oncol Res, 2009, 15(3): 487-493.
  • 9Huang JJ, Li HR, Huang Y, et al. Beclin 1 expression: a predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type[J]. Autophagy, 2010, 6(6): 777-783.
  • 10Oberstein A, Jeffrey PD, Shi Y. Crystal structure of the Bcl-XL-Beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein[J]. J Biol Chem, 2007, 282(17): 13123-13132.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部